MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking... MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP.
- Mechanism
- Curator reviewed
MEM 1414 is PDE4 inhibitor which is designed to selectively raise levels of cyclic adenosine monophosphate, or cAMP, by inhibiting the activity of PDE4, the enzyme which breaks down cAMP, and therefore they may be beneficial in restoring memory function. PDE4 inhibitors may also have potential therapeutic value in multiple other indications.
- Primary indication
- Investigated for use/treatment in alzheimer's disease, depression, memory loss, and neurologic disorders.Curator reviewed
- Code names
- MEM 1414
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with MEM 1414, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account